This Article Full Text Full Text (PDF) All Versions of this Article: 40/7/2539    most recent STROKEAHA.108.543991v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Subramanian, S. Articles by Offner, H. Search for Related Content PubMed PubMed Citation Articles by Subramanian, S. Articles by Offner, H. Related Collections Animal models of human disease Neuroprotectors

(Stroke. 2009;40:2539.)
© 2009 American Heart Association, Inc.

Original Contributions

Recombinant T Cell Receptor Ligand Treats Experimental Stroke

Sandhya Subramanian, MS; Bing Zhang, MD; Yasuharu Kosaka, MD; Gregory G. Burrows, PhD; Marjorie R. Grafe, MD, PhD; Arthur A. Vandenbark, PhD; Patricia D. Hurn, PhD Halina Offner, DrMed

From Neuroimmunology Research (S.S., A.A.V., H.O.), Veterans Affairs Medical Center, Portland, Ore; and the Departments of Anesthesiology and Perioperative Medicine (B.Z., Y.K., M.R.G., P.D.H., H.O.), Neurology (G.G.B., A.A.V., H.O.), Molecular Microbiology and Immunology (A.A.V.), and Pathology (M.R.G.), Oregon Health & Science University, Portland, Ore.

Correspondence to Halina Offner, DrMed, Portland VA Medical Center, R&D-31, 3710 SW US Veterans Hospital Road, Portland, OR 97239. E-mail offnerva{at}ohsu.edu

Background and Purpose— Experimental stroke induces a biphasic effect on the immune response that involves early activation of peripheral leukocytes followed by severe immunodepression and atrophy of the spleen and thymus. In tandem, the developing infarct is exacerbated by influx of numerous inflammatory cell types, including T and B lymphocytes. These features of stroke prompted our use of recombinant T cell receptor ligands (RTL), partial major histocompatibility complex Class II molecules covalently bound to myelin peptides. We tested the hypothesis that RTL would improve ischemic outcome in the brain without exacerbating defects in the peripheral immune system function.

Methods— Four daily doses of RTL were administered subcutaneously to C57BL/6 mice after middle cerebral artery occlusion, and lesion size and cellular composition were assessed in the brain and cell numbers were assessed in the spleen and thymus.

Results— Treatment with RTL551 (I-A^b molecule linked to MOG-35-55 peptide) reduced cortical and total stroke lesion size by approximately 50%, inhibited the accumulation of inflammatory cells, particularly macrophages/activated microglial cells and dendritic cells, and mitigated splenic atrophy. Treatment with RTL1000 (HLA-DR2 moiety linked to human MOG-35-55 peptide) similarly reduced the stroke lesion size in HLA-DR2 transgenic mice. In contrast, control RTL with a nonneuroantigen peptide or a mismatched major histocompatibility complex Class II moiety had no effect on stroke lesion size.

Conclusions— These data are the first to demonstrate successful treatment of experimental stroke using a neuroantigen-specific immunomodulatory agent administered after ischemia, suggesting therapeutic potential in human stroke.

Key Words: autoreactive T cells • immunotherapy • recombinant TCR ligands • stroke